Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Schering-Plough Backs Out Of Asentar Agreement With Novacea

Apr 09 2008

• By Brooke McManus

Related Content

Novacea Terminates Asentar Phase III For Prostate Cancer, But Sees Hope For Treatment In Pancreatic Cancer

Nov 05 2007

Schering-Plough Cutback Target: $1.5 Billion

Apr 02 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window